Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease

Objective: To review the pharmacology, efficacy, and safety of the first nebulized long-acting muscarinic antagonist (LAMA), glycopyrrolate (GLY)/eFlow closed system (CS) nebulizer, approved for maintenance treatment of chronic obstructive pulmonary disease (COPD). Data Sources: A PubMed search was...

Descripción completa

Detalles Bibliográficos
Autor principal: Pleasants, Roy A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review Articles-New Drug Approval
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357169/
https://www.ncbi.nlm.nih.gov/pubmed/30175596
http://dx.doi.org/10.1177/1060028018798753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357169/
https://www.ncbi.nlm.nih.gov/pubmed/30175596
http://dx.doi.org/10.1177/1060028018798753

Ejemplares similares